Literature DB >> 23896941

Prostatic biopsies in selected men aged 75 years and older guide key clinical management decisions.

A L Paterson1, M K Sut, A R Khan, H K Sharma.   

Abstract

PURPOSE: Increasing life expectancy and PSA testing has increased the number of men over the age of seventy-five presenting for investigation of potential prostate malignancies. Prostatic biopsies provide diagnostic information; however, they are invasive and may not alter management decisions. Therefore, this study aimed to investigate whether prostate biopsies in this age group were justified.
MATERIALS AND METHODS: All men aged 75 years and older who underwent prostatic biopsies between January 2010 and November 2011 at Bedford Hospital were identified and the indication for the biopsies, histopathological results and subsequent management plan investigated.
RESULTS: One hundred and thirty-eight (138) prostatic biopsies were undertaken and malignancies identified in 60/138 (43 %) cases. Prebiopsy PSA and examination findings had a poor positive predictive value of 54 %. Fifty-five out of sixty (92 %) cancers were classified as high or medium risk disease with 30/60 (50 %) patients commencing radiotherapy treatment with curative intent.
CONCLUSION: In selected patients aged 75 years or over, prostatic biopsies provide important diagnostic information which directly impacts on clinical decisions, supporting their use in this age group.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23896941     DOI: 10.1007/s11255-013-0506-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

1.  Screening for prostate cancer among men 75 years of age or older.

Authors:  Michael J Barry
Journal:  N Engl J Med       Date:  2008-12-11       Impact factor: 91.245

Review 2.  Prostate biopsy: who, how and when. An update.

Authors:  Bob Djavan; Shirin Milani; Mesut Remzi
Journal:  Can J Urol       Date:  2005-02       Impact factor: 1.344

3.  Increased risk of rectal cancer after prostate radiation: a population-based study.

Authors:  Nancy N Baxter; Joel E Tepper; Sara B Durham; David A Rothenberger; Beth A Virnig
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

4.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

5.  PSA screening among elderly men with limited life expectancies.

Authors:  Louise C Walter; Daniel Bertenthal; Karla Lindquist; Badrinath R Konety
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

Review 6.  The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review.

Authors:  Patricia Harnden; Michael D Shelley; Hayley Clements; Bernadette Coles; R Sandy Tyndale-Biscoe; Brian Naylor; Malcolm D Mason
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

7.  Survival associated with treatment vs observation of localized prostate cancer in elderly men.

Authors:  Yu-Ning Wong; Nandita Mitra; Gary Hudes; Russell Localio; J Sanford Schwartz; Fei Wan; Chantal Montagnet; Katrina Armstrong
Journal:  JAMA       Date:  2006-12-13       Impact factor: 56.272

8.  Prostate cancer in elderly men.

Authors:  Anton Stangelberger; Matthias Waldert; Bob Djavan
Journal:  Rev Urol       Date:  2008

9.  Prostate-specific antigen screening in elderly men.

Authors:  Grace Lu-Yao; Therese A Stukel; Siu-Long Yao
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

10.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.